Translating Research Into HIV-related Health Outcomes In The Developing World
Funder
National Health and Medical Research Council
Funding Amount
$714,745.00
Summary
Professor Crowe's research addresses important health issues for HIV infected people living in resource limited countries. Her team validates low cost point of care tests to monitor HIV infection, including a test she co-developed to determine when to start anti-HIV treatment, and investigates how these low cost tests can improve clinical care of people with HIV and TB. In addition she will determine how changes in the immune system increase the risk of heart attacks in young HIV patients.
Randomised Trial To Determine The Safety And Efficacy Of Early Vs Deferred Treatment Of HIV
Funder
National Health and Medical Research Council
Funding Amount
$1,070,331.00
Summary
Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future res ....Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future research for many years to come.Read moreRead less
A Randomised Trial To Compare Dolutegravir+darunavir/r Versus Recommended Standard Of Care Antiretroviral Regimens In Patients With HIV Infection Who Have Failed Recommended First Line Therapy
Funder
National Health and Medical Research Council
Funding Amount
$2,323,209.00
Summary
Public sector programs for provision of antiretroviral drugs in developing countries need regimens of therapy that are safe, effective and simple to administer. The evidence base to support first line therapy is strong. This contrasts with a relative paucity of evidence for second regimens of therapy once first line effectiveness has been lost. This trial will address that evidential deficit and support evidence-based recommendations for global health.
Identification And Quantification Of HIV Latency Biomarkers In The Central Nervous System
Funder
National Health and Medical Research Council
Funding Amount
$814,618.00
Summary
One major obstacle in curing HIV is the brain’s role as a potential reservoir of HIV infection. It is unknown if “reawakening” of HIV may lead to uncontrollable brain damage given that current antiretroviral drugs vary in their ability to treat brain infection. Not all patients have HIV brain infection so eradication therapies in themselves may be safe. We aim to identify and quantify biomarkers of HIV latency in the brain to stratify patients into these two cohorts.
Understanding And Preventing Chronic Disease In People Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$367,946.00
Summary
Australia’s ageing population is increasingly at risk of chronic diseases such as heart disease and diabetes. For Australians who are living with HIV, these diseases occur more frequently and at an earlier age. I will be investigating the underlying reasons for this increase in risk and will test innovative online systems that help people living with HIV reduce their risk of chronic disease. This work will provide important information for Australians at risk of developing chronic disease.
Understanding The Establishment Of HIV Reservoirs And Development Of HIV Eradication Strategies
Funder
National Health and Medical Research Council
Funding Amount
$380,891.00
Summary
Understanding why, when, how and at what pace the HIV virus hides and establishes itself in one's body will allow us to design new ways for preventing and eliminating this reservoir of hidden HIV. As a clinician scientist in HIV and infectious diseases, I will drive clinical studies to explore the kinetics of HIV in patients who recently acquired HIV, those who start HIV treatment early, and those chronically infected with HIV so as to investigate novel means to minimise HIV hiding spots.
The development of cures, vaccines and better treatments for HIV/AIDS is an urgent global health priority. This team of seven groups in Sydney and Melbourne will study how HIV can lie dormant in some parts of the body, evading eradication by HIV therapy, as well as how the immune system responds to the virus. This will allow for design of novel vaccines and treatments. The researchers have skills in basic virology and immunology, and translating laboratory findings into human clinical trials.
The Primary HIV Combined United Database (PCUD) is the largest database of patients with primary HIV infection in Australia. Dating back to 1983, it collects data from people with HIV seroconversion. Primary HIV infection, or seroconversion provides a unique opportunity to study HIV throughout its natural history. This study aims to link data on long term health outcomes such as AIDS, cancer and cardiovascular disease in this cohort, which can then be used to understand the determinants of progr ....The Primary HIV Combined United Database (PCUD) is the largest database of patients with primary HIV infection in Australia. Dating back to 1983, it collects data from people with HIV seroconversion. Primary HIV infection, or seroconversion provides a unique opportunity to study HIV throughout its natural history. This study aims to link data on long term health outcomes such as AIDS, cancer and cardiovascular disease in this cohort, which can then be used to understand the determinants of progression and complications of HIV infection.Read moreRead less
Enhancing The Cascade Of HIV Care To Maximise The Prevention Benefits Of Antiretroviral Therapy For Populations Living With HIV
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
Antiretroviral drugs are effective at preventing death and illness for populations with HIV and preventing HIV transmission. I will undertake a series of studies to measure the impact of current antiretroviral treatment to prevent both illness and new infections in Australia. I will also undertake a series of studies to increase HIV testing, diagnose HIV earlier, and improve people’s linkage and retention HIV in care and evaluate the impact of these interventions on HIV transmission.
The Pharmacokinetic, Pharmacodynamic And Pharmacogenomic Outcomes Of Reduced Dosage Of Efavirenz: The Encore1 Study
Funder
National Health and Medical Research Council
Funding Amount
$1,234,943.00
Summary
Our primary aim is to assess blood concentrations of a drug called efavirenz, an important drug used in the treatment of HIV infection and associate these with variability of genes that control metabolism of the drug. A better understanding of gene variability and how it relates to safety and efficacy outcomes at a reduced, compared to a standard dose of efavirenz could support improved treatment of HIV disease.